Lipum AB – interim report for the period January-June 2023

Lipum AB (publ) has published the interim report for period January to June for 2023. Below is a summary, a complete report (only in Swedish) is available on the company’s website.

CEO Einar Pontén comments: “I am very pleased with this development. We will now accelerate the implementation of our Phase 1 clinical trial.”

Financial summary January – June 2023

  • Net sales: KSEK 0 (0)
  • Result after financial items: -21 122 KSEK (-15 167)
  • Cash and cash equivalents as of June 31: 12 364 KSEK (18 783)

Significant events during the period January – June 2023

  • Carl-Johan Spak was elected as new board member of Lipum AB.
  • Lipum had a consultative meeting with the Swedish Medical Products Agency.
  • Decision on rights issue.

Significant events after the period

  • Capital contribution from rights issue 15.3 MSEK before overheads of 8%.
  • Collaboration with researchers at Karolinska Institute initiated.
  • Publication of a scientific article on BSSL.

CEO Einar Pontén comments on the report in a live webcast on August 31 at 09:00, link.

Contacts
Einar Pontén, CEO
einar.ponten@lipum.se
+46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Links